AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo.
AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo.
复制标题
DOI:
10.1186/s13036-021-00276-3
复制
发表时间:
2021-10-21
影响因子:
5.6
通讯作者:
Won Y
中科院分区:
文献类型:
--
作者:
Cha BH;Jung M;Kim AS;Lepak VC;Colson BA;Bull DA;Won Y
Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and pathology in hypertrophy. AZD2014 is a small-molecule ATP competitive mTOR inhibitor working on both mTORC1 and mTORC2 complexes. Little is known about the therapeutic effects of AZD2014 in cardiac hypertrophy and its underlying mechanism. Here, AZD2014 is examined in in vitro model of phenylephrine (PE)-induced human cardiomyocyte hypertrophy and a myosin-binding protein-C (Mybpc3)-targeted knockout (KO) mouse model of cardiac hypertrophy. Our results demonstrate that cardiomyocytes treated with AZD2014 retain the normal phenotype and AZD2014 attenuates cardiac hypertrophy in the Mybpc3-KO mouse model through inhibition of dual mTORC1 and mTORC2, which in turn results in the down-regulation of the Akt/mTOR signaling pathway. The online version contains supplementary material available at 10.1186/s13036-021-00276-3.
登录
查看更多内容
影响因子:
--
作者:
Markman B;Dienstmann R;Tabernero J
通讯作者:
Tabernero J
DOI:
10.1073/pnas.85.2.339
发表时间:
1988-01-01
影响因子:
11.1
作者:
IZUMO, S;NADALGINARD, B;MAHDAVI, V
通讯作者:
MAHDAVI, V
影响因子:
37.8
作者:
MARON, BJ;GARDIN, JM;BILD, DE
通讯作者:
BILD, DE
影响因子:
2.8
作者:
Samak M;Fatullayev J;Sabashnikov A;Zeriouh M;Schmack B;Farag M;Popov AF;Dohmen PM;Choi YH;Wahlers T;Weymann A
通讯作者:
Weymann A
影响因子:
20.1
作者:
SADOSHIMA, J;IZUMO, S
通讯作者:
IZUMO, S